Luis Ruiz Guerrero

Danicamtiv enhanced cardiac myosin function in vitro and was generally well tolerated in #DCM. Echo findings suggest improved contractility, with strongest responses in #MYH7 and TTN cohorts jacc.org/doi/10.1016/j.… #JACC #cvDCM

Early-onset AF, especially without risk factors --> myocardial disease --> genetic evaluation medrxiv.org/content/10.110… #CardioTwitter

RBM20 cardiomyopathy carries a more significant burden at a younger age, and an accelerated course compared to TTN cardiomyopathy pmc.ncbi.nlm.nih.gov/articles/PMC11… #CardioTwitter

A deep dive into the mechanisms of ALPK3 associated HCM #CardioTwitter nature.com/articles/s4159…

📣New Consensus is out in #Europace #EHRA2025 💊The diagnostic role of pharmacological provocation testing in cardiac electrophysiology💥 🔗 doi.org/10.1093/europa… @GiulioConte9 @Dominik_Linz @FraSantoroMD @AndyZhangMD @DavideMei93 @marcovitoloMD @LuigiDiBiaseMD

Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25. Check out the key findings ➡️ bit.ly/3DYGHEl

Late Gadolinium Enhancement in Early Repolarization Syndrome heartrhythmjournal.com/article/S1547-…

📅 The A Coruña Hypertrophic Cardiomyopathy Congress is Back! 🗓 September 18-19, 2025 🔬 Experts from 🇦🇷 🇦🇺 🇩🇪 🇪🇸 🇫🇷 🇬🇧 🇮🇹 🇳🇱 🇵🇹 🇺🇸 @seccCFyGenetCV @secardiologia 🔗 hypertrophiccardiomyopathyacoruna.com/topics/

Low penetrance sarcomere variants (LowSVs) contribute to mild HCM alone but increase severity with high-risk variants. @neallakdawala @drjamesware @tikuowens @jodieingles27 @S2beri @sday_hcm @SeanLZheng @AdamHelmsMD ahajournals.org/doi/abs/10.116…

🧬 24% of patients with heritable arrhythmias & cardiomyopathies carry a disease-causing variant—but only 8% see changes in clinical management. How do we close the gap? Read the study: jacc.org/doi/10.1016/j.… #JACC #Genetics #CardioScience #PrecisionMedicine #cvGenetics

Cardiopulmonary exercise testing (CPET) has a unique role in the assessment of cardiopulmonary disease. @BrazileTiffany and colleagues review key CPET variables, protocols and clinical indications. eviden.cc/4aC6uOt

Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors. Learn more: nej.md/4h41K6k

🔬New in @JACCJournals: HCM diagnosis criteria show unexpected demographic bias. Study of 50,000+ hearts reveals current thresholds create 8:1 male-female ratio Proposing demographic-adjusted thresholds to improve diagnosis🫀 authors.elsevier.com/a/1kPE52d9GH~T… @UCL_ICS @NHSBartsHealth

I am very happy to end 2024 with the publication of our study "Validation of a hand-held ultrasound device in the evaluation of aortic stenosis". Thanks to all the collaborators @raquelpbarquin #AdrianMargarida @HUnivValdecilla @IDIVALdecilla link.springer.com/10.1007/s10554…

This is nice work on an important question in EP. I have an idea about a subgroup. Mandrola theory of de novo AFlutter. If it occurs in pt w prior heart surgery, CTI likely enough. If no prior surgery, CTI + PVI better. #epeeps LOE 👆= opinion. #EPeeps

As promised, here is a slew of content ...re the PLATO trial of ticagrelor vs clopidogrel in patients with ACS This all occurred in 2009, early in my critical appraisal learning. Revisiting PLATO controversy is super important--both clinically and epistemologically

🗝️ Collecting a detailed family history and pertinent clinical data for patients with cardiomyopathies is needed to guide potential use of genetic testing. Read more key points on genetic testing for cardiomyopathies ➡️ bit.ly/4fho5vK #HeartFailure

2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee | Journal of the American College of Cardiology jacc.org/doi/10.1016/j.…

How to include mDNA in HCM genetic panels? humgenomics.biomedcentral.com/articles/10.11…

#AHA24 Looks like a big win, but it is not. Another trial designed to be + Endpoint driven by a handful of HF events. (Unblinded b/c pts know they are on GLP1 CV death numerically higher in Tirzepatide group Total hospitalizations not reported -- I suspect they are not reduced Same story as empagliflozin and finerenone HF trials are not the same as they used to be